Published online May 27, 2021. doi: 10.4240/wjgs.v13.i5.476
Peer-review started: January 29, 2021
First decision: March 6, 2021
Revised: March 13, 2021
Accepted: April 28, 2021
Article in press: April 28, 2021
Published online: May 27, 2021
Processing time: 111 Days and 22.6 Hours
The treatment of hepatocellular carcinoma (HCC) larger than 10 cm remains challenging. The Chang Gung Research Database (CGRD) contains all medical records of the Chang Gung Memorial Foundation and has become one of the largest clinical databases worldwide. By utilizing the data from CGRD, we attempted to analyze the outcome of HCC larger than 10 cm.
Owing to advancement in surgical technique and perioperative care, the surgical risks associated with liver resection are decreasing in the recent decades. However, the surgical outcome regarding HCC larger than 10 cm has not been updated.
We aimed to consolidate the role of surgical resection for HCC larger than 10 cm. The survival outcomes between surgery and transarterial chemoembolization (TACE) were also compared.
Eligible HCC patients were identified from the CGRD, and two models were adopted: The surgical outcome between HCC ≥ 10 cm (L-HCC) and HCC < 10 cm (S-HCC) (model 1); the survival of L-HCC after either liver resection or TACE (model 2). To eliminate the potential confounding bias originating from heterogeneous baseline features and disproportionate case numbers, inverse-probability of treatment weighting between different groups was adopted.
Although worse than the S-HCC, the surgical and long-term oncological outcome of L-HCC had improved in the recent decades. Moreover, surgery could provide a better survival outcome for L-HCC than TACE.
With acceptable performance status and liver functional reserve, we suggest liver resection should be conducted for HCC larger than 10 cm. Due to its inferior survival, T1 stage should be further sub-divided to predict precisely patient outcome.
The current study demonstrated the inferior survival of L-HCC. The necessity of adjuvant therapy following liver resection for L-HCC should thus be determined by further randomized controlled trials.